Sphingosine Kinase-1 Activation Causes Acquired Resistance Against Sunitinib in Renal Cell Carcinoma Cells

Cell Biochemistry and Biophysics

Volumn 68, Issue 2, 2014, Pages 419-425

  Gao, Hui ^a   Deng, Lichun ^b  

^a QINGDAO UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

ERK; Renal cell carcinoma; SK1; Sunitinib

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2-(2-AMINO-3-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; ANTINEOPLASTIC AGENT; FLAVONOID; INDOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOTRANSFERASE; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PYRROLE DERIVATIVE; SPHINGOSINE KINASE; SUNITINIB;

ARTICLE; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYME ACTIVATION; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; HUMANS; INDOLES; KIDNEY NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PYRROLES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 84893955445     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-013-9723-4     Document Type: Article

References (35)

1. Antonelli, A., et al. (2007). The follow-up management of non-metastatic renal cell carcinoma: Definition of a surveillance protocol. BJU International, 99(2), 296-300.
2. Itsumi, M., & Tatsugami, K. (2010). Immunotherapy for renal cell carcinoma. Clinical and Developmental Immunology, 2010, 284581.
3. Faivre, S., et al. (2007). Molecular basis for sunitinib efficacy and future clinical development. Nature Reviews. Drug Discovery, 6(9), 734-745.
4. Irani, J. (2007). Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma. Progres en Urologie, 17(5), 996.
5. Motzer, R. J., et al. (2007). Sunitinib efficacy against advanced renal cell carcinoma. Journal of Urology, 178(5), 1883-1887.
6. Huang, D., et al. (2010). Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Research, 70(3), 1063-1071.
7. Farber, E., & Rubin, H. (1991). Cellular adaptation in the origin and development of cancer. Cancer Research, 51(11), 2751-2761.
8. Song, L., et al. (2011). Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3 K/Akt/NF-kappaB pathway in human non-small cell lung cancer. Clinical Cancer Research, 17(7), 1839-1849.
9. Marfe, G., et al. (2011). Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. Experimental Hematology, 39(6), 653-665.
10. Rupal S, B., et al. Sphingosine-1-phosphate (S1P) as a novel target in renal cancer (RCC). in AACR 101st Annual Meeting 2010. 2011. Washington, DC: Cancer Research.
11. Kuroda, K., et al. (2009). Activated Akt prevents antitumor activity of gefitinib in renal cancer cells. Urology, 74(1), 209-215.
12. Martinelli, E., et al. (2010). Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clinical Cancer Research, 16(20), 4990-5001.
13. Morgillo, F., et al. (2011). Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PLoS One, 6(12), e28841.
14. Cho, S. Y., et al. (2011). Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1alpha inactivation in hypoxic PC-3 prostate cancer cells. Journal of Pineal Research, 51(1), 87-93.
15. Abrams, T. J., et al. (2003). SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Molecular Cancer Therapeutics, 2(5), 471-478.
16. Chow, L. Q., & Eckhardt, S. G. (2007). Sunitinib: from rational design to clinical efficacy. Journal of Clinical Oncology, 25(7), 884-896.
17. Rubinson, D. A., et al. (2003). A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nature Genetics, 33(3), 401-406.
18. Li, H., et al. (2011). Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Advances in Medical Sciences, 56(2), 275-284.
19. Pchejetski, D., et al. (2011). Therapeutic potential of targeting sphingosine kinase 1 in prostate cancer. Nature Reviews Urology, 8(10), 569-678.
20. Huang, D., et al. (2010). Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Research, 70(3), 1053-1062.
21. Olson, P., et al. (2011). Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 108(49), E1275-E1284.
22. Powles, T., et al. (2011). Sunitinib and other targeted therapies for renal cell carcinoma. British Journal of Cancer, 104(5), 741-745.
23. Mendel, D. B., et al. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research, 9(1), 327-337.
24. Schueneman, A. J., et al. (2003). SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Research, 63(14), 4009-4016.
25. Tanaka, Y., et al. (2011). Sunitinib suppresses tumor growth and metastases in a highly metastatic mouse mammary cancer model. Anticancer Research, 31(4), 1225-1234.
26. Seandel, M., et al. (2006). The activity of sunitinib against gastrointestinal stromal tumor seems to be distinct from its antiangiogenic effects. Clinical Cancer Research, 12(20 Pt 1), 6203-6204.
27. de Bouard, S., et al. (2007). Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. Neuro-Oncology, 9(4), 412-423.
28. Xin, H., et al. (2009). Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Research, 69(6), 2506-2513.
29. Oliner, J., et al. (2004). Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell, 6(5), 507-516.
30. Cenni, E. (2005). Inhibition of angiogenic activity of renal carcinoma by an antisense oligonucleotide targeting fibroblast growth factor-2. Anticancer Research, 25(2A), 1109-1113.
31. Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 8(8), 592-603.
32. Cuvillier, O., et al. (2010). Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Current Molecular Pharmacology, 3(2), 53-65.
33. Pyne, N. J., & Pyne, S. (2010). Sphingosine 1-phosphate and cancer. Nature Reviews Cancer, 10(7), 489-503.
34. Hu, S., et al. (2009). Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clinical Cancer Research, 15(19), 6062-6069.
35. Shukla, S., et al. (2009). Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2. Drug Metabolism and Disposition, 37(2), 359-365.